<DOC>
	<DOCNO>NCT01323569</DOCNO>
	<brief_summary>This crossover study six treatment session evaluate abuse potential three dos Sativex compare Marinol placebo , subject history recreational marijuana use .</brief_summary>
	<brief_title>Abuse Potential Sativex</brief_title>
	<detailed_description>Subjects attend two-session , randomize , double-blind , crossover qualification receive positive control drug ( Marinol 30 mg ) match placebo 48 hour apart randomize fashion . To qualify , subject must discriminate Marinol placebo . Eligible subject go main study divide six treatment session separate 7-21 day . Serial pharmacodynamic evaluation take treatment session well occasional pharmacokinetic blood sample verify proof exposure . In addition , safety monitoring include regular assessment vital sign , telemetry , 12-lead ECG , clinical laboratory test adverse event ( AEs ) .</detailed_description>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Healthy male female subject , 19 45 year age , inclusive . Current recreational marijuana user , define use smoke marijuana , hashish , oral THC , least week 3 month prior screen , least one occasion , four time give week 3 month prior screen . Body mass index within range 19 30 kg/m2 inclusive minimum weight least 50 kg screening . Free clinically significant abnormality , assess screening , basis medical history , vital sign , physical examination , 12lead ECG , clinical laboratory test , include haematology , clinical chemistry , urinalysis , serology , judge investigator designee . A positive urine THC drug screen screen qualification , confirm quantitative analysis ; level must least 50 ng THC/mL . A negative urine drug screen cocaine , opiates , amphetamine , benzodiazepine upon admission screening , qualification session , treatment session . Subjects positive urine drug screen upon presentation study visit could reschedule another session discretion investigator . All female subject require negative serum pregnancy test screen negative urine pregnancy test prior qualification session drug treatment session . Subjects reproductive potential could enter study use willing continue use two method contraception duration study . These method include male condom men addition oral contraceptive , contraceptive implant injection , intrauterine device , diaphragm , contraceptive sponge woman . Adequate protection , define , use least 1 month prior screening , exception oral contraceptive , use least 3 month prior screen . These method continually use 30 day end study . Subjects surgically sterilize ( tubal ligation , hysterectomy , vasectomy ) postmenopausal least 2 year ( history ) consider reproductive potential . Subjects pass qualification session . Must understood provide write informed consent , prior initiation protocolspecific procedure . Subjects able comply study procedure . Negative breath alcohol test . Subjects positive breath alcohol test could reschedule discretion investigator . History presence drug alcohol dependence ( exclude nicotine caffeine ) , include subject ever drug rehabilitation program . Clinically important impairment dysfunction body system , include , limited , follow : cardiovascular , haematological , hepatic , gastrointestinal , renal , pulmonary , neurological , judged investigator designee . Any known suspected history ( include family history ) schizophrenia psychotic illness . Presence history psychiatric disorder , organic brain disorder , seizure disorder deem clinically significant investigator . History hypersensitivity allergy cannabinoids , cannabis and/or metabolite , study drug excipients , similar compound ( propylene glycol , ethanol , peppermint , sesame oil ) allergic reaction medication . Consumed caffeinecontaining beverage excess 450 mg caffeine ( e.g . 5 cup tea 3 cup regular coffee 8 can cola ) per day 6 month prior screen . Consumed great 20 cigarette per day . Treatment another investigational nonapproved drug , within 4 week prior start qualification session dosing ( Day 1 ) . Donated lose blood ( &gt; 100 mL ) within 30 day prior screen . Female subject pregnant lactate plan become pregnant within 60 day last study drug administration . Used prescription drug ( except oral contraceptive sex hormone replacement ) , include smoke THC medicinal purpose , within 14 day qualification session duration study , unless opinion investigator ( designee ) , medication receive would interfere study procedure data integrity compromise safety subject . Used nonprescription drug natural health product acetaminophen 2 g per day vitamin mineral supplement ( include mega dose vitamin therapy ) , within 7 day prior qualification session , duration study , unless opinion investigator ( designee ) , medication receive would interfere study procedure data integrity compromise safety subject . Uncontrolled hypertension screen judge clinically significant investigator ( designee ) . Subjects , opinion investigator ( designee ) . willing , able capable follow study schedule reason . Subjects positive treat hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) . Subjects face current pending legal charge .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Sativex</keyword>
	<keyword>Cannabinoids</keyword>
	<keyword>Abuse potential</keyword>
	<keyword>Addiction</keyword>
</DOC>